Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

10-year clinical outcomes of subthalamic nucleus versus pallidal deep brain stimulation for Parkinson's disease: VA/NINDS CSP #468F.

Frontiers in neurology·2026
Same author

Peripheral monocyte transcriptional signatures of inflammation and oxidative stress in Parkinson's disease.

Frontiers in immunology·2025
Same author

Cyclic Vomiting Syndrome as a Migraine Variant in Adults: A Case Report.

Pain medicine case reports·2025
Same author

Usability and Tolerability of Virtual Reality-Based Cognitive Stimulation in Healthy Elderly Volunteers-A Feasibility Clinical Trial.

Games for health journal·2024
Same author

Prevalence of Delirium After Abdominal Surgery and Association With Ketamine: A Retrospective, Propensity-Matched Cohort Study.

Critical care explorations·2024
Same author

West Nile virus encephalomyelitis in an immunocompromised patient.

Radiology case reports·2023

Related Experiment Video

Updated: Mar 12, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Post-stroke dyskinesias.

Mohammad Obadah Nakawah1, Eugene C Lai1

  • 1Stanely H. Appel, Department of Neurology, Houston Methodist Neurological Institute, Houston, TX, USA.

Neuropsychiatric Disease and Treatment
|November 18, 2016
PubMed
Summary
This summary is machine-generated.

Strokes can cause secondary movement disorders in elderly patients, specifically uncommon vascular dyskinesias. These hyperkinetic movements often resolve within a year, though treatment may be needed for severe cases.

Keywords:
movement disordersstrokevascular dyskinesia

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

8.1K

Related Experiment Videos

Last Updated: Mar 12, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

8.1K

Area of Science:

  • Neurology
  • Movement Disorders
  • Cerebrovascular Disease

Background:

  • Strokes (ischemic or hemorrhagic) are common causes of secondary movement disorders in the elderly.
  • Stroke-related (vascular) movement disorders are uncommon but present a broad spectrum of hypo- and hyperkinetic syndromes.
  • Post-stroke dyskinesias are involuntary hyperkinetic movements resulting from cerebrovascular insults, often with mixed phenotypes.

Approach:

  • Phenomenological categorization of post-stroke dyskinesias based on the most relevant motor phenotype.
  • Guiding treatment strategies through accurate classification of dyskinesia.
  • Evaluating the typical self-limiting course (6-12 months) of post-stroke dyskinesias.

Key Points:

  • Post-stroke dyskinesias can be challenging to classify due to mixed hyperkinetic phenotypes.
  • Identification of the primary motor phenotype is crucial for targeted treatment.
  • Most cases are self-limiting, resolving within 6 to 12 months.

Conclusions:

  • Pharmacotherapy may be required for short-term symptom management of post-stroke dyskinesias.
  • Functional neurosurgery targeting the motor thalamus or globus pallidus interna is an option for severe, persistent cases (>12 months).
  • Understanding the specific motor phenotype aids in managing these uncommon vascular complications.